Cross-Sector entity

CORALreef Clinical Trials

event
9

CORALreef Clinical Trials is most often covered alongside Amgen, which appears in 2 of these 2 stories. fda-approval accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 132 original sources on average.

2 verified stories tracked

Last mentioned: Jul 16, 2026

Entity pulse

Recent coverage · CORALreef Clinical Trials

2 stories
9 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about CORALreef Clinical Trials

CORALreef Clinical Trials is most often covered alongside Amgen, which appears in 2 of these 2 stories. fda-approval accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 132 original sources on average. We currently track 2 Cross-Sector stories that mention CORALreef Clinical Trials, all published on July 16, 2026.

Stories tracked
2
Sources per story
132

Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering CORALreef Clinical Trials. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. FDA Approves Lipfendra

    The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction.

Stories mentioning CORALreef Clinical Trials 2